INFUSIONAL CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE IN RELAPSED AND RESISTANT NON-HODGKINS-LYMPHOMA - EVIDENCE FOR A SCHEDULE-DEPENDENT EFFECT FAVORING INFUSIONAL ADMINISTRATION OF CHEMOTHERAPY

被引:61
作者
SPARANO, JA [1 ]
WIERNIK, PH [1 ]
LEAF, A [1 ]
DUTCHER, JP [1 ]
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED, JACK WEILER HOSP, BRONX, NY 10461 USA
关键词
D O I
10.1200/JCO.1993.11.6.1071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study attempted to determine the efficacy of cyclophosphamide (C), doxorubicin (D), and etoposide (E) administered as a continuous intravenous (IV) infusion (infusional CDE) over 4 days in patients with relapsed or resistant non-Hodgkin's lymphoma (rNHL) and in patients with previously untreated (uNHL) who had poor prognostic features. Patients and Methods: Fifty-eight patients with rNHL and 10 patients with uNHL received infusional CDE every 28 or more days; all but one had intermediate- to high- grade histology. The cumulative doses of C, D, and E administered per treatment cycle were 750 mg/m2, 50 mg/m2, and 240 mg/m2, respectively. In the rNHL group, all patients had previously received C, most (81%) had received D, and a minority (16%) had received E. Results: Objective response occurred in 30 patients with rNHL (52%; 95% confidence interval, 39% to 65%); 10 patients had a complete response (CR) (17%; 95% confidence interval, 7% to 27%). Eleven patients (19%) remain progression-free (median follow-up, 22 months; range, 10+ to 38+), and six patients (10%) are disease-free (median follow-up, 25 months; range, 10+ to 38+). Among 10 patients with uNHL, eight (80%) had a CR, and none have relapsed (median follow-up, 11 months; range, 9+ to 24+). Toxicity was primarily hematologic. Two treatment-related deaths (3%) occurred, both attributable to infection in the relapsed or resistant group. Conclusion: Infusional CDE produced a CR in substantial proportion of patients who had previously been exposed to at least two of the agents administered as an IV bolus, suggesting a schedule-dependent effect in favor of the infusional administration of certain cytotoxic agents in patients with lymphoid neoplasms. In addition, infusional CDE was effective and tolerable in patients with poor-prognosis NHL when used as initial therapy, and merits further study in that setting.
引用
收藏
页码:1071 / 1079
页数:9
相关论文
共 30 条
[11]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[12]  
KAPLAN L D, 1989, Journal of the American Medical Association, V261, P719, DOI 10.1001/jama.261.5.719
[13]   REDUCTION OF DOXORUBICIN CARDIOTOXICITY BY PROLONGED CONTINUOUS INTRAVENOUS-INFUSION [J].
LEGHA, SS ;
BENJAMIN, RS ;
MACKAY, B ;
EWER, M ;
WALLACE, S ;
VALDIVIESO, M ;
RASMUSSEN, SL ;
BLUMENSCHEIN, GR ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (02) :133-139
[14]  
LEVINE AM, 1992, KBLOOD, V80, P8
[15]  
LOKICH JJ, 1986, CANCER, V58, P1020, DOI 10.1002/1097-0142(19860901)58:5<1020::AID-CNCR2820580506>3.0.CO
[16]  
2-9
[17]   TIME-SCHEDULE DEPENDENCY OF THE INHIBITING ACTIVITY OF VARIOUS ANTICANCER DRUGS IN THE CLONOGENIC-ASSAY [J].
MATSUSHIMA, Y ;
KANZAWA, F ;
HOSHI, A ;
SHIMIZU, E ;
NOMORI, H ;
SASAKI, Y ;
SAIJO, N .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (02) :104-107
[18]   THE ROLE OF DOSE INTENSITY IN DETERMINING OUTCOME IN INTERMEDIATE-GRADE NON-HODGKINS-LYMPHOMA [J].
MEYER, RM ;
HRYNIUK, WM ;
GOODYEAR, MDE .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :339-347
[19]   P-GLYCOPROTEIN EXPRESSION IN MALIGNANT-LYMPHOMA AND REVERSAL OF CLINICAL DRUG-RESISTANCE WITH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL [J].
MILLER, TP ;
GROGAN, TM ;
DALTON, WS ;
SPIER, CM ;
SCHEPER, RJ ;
SALMON, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :17-24
[20]   ETOPOSIDE (VP-16-213) - CURRENT STATUS OF AN ACTIVE ANTICANCER DRUG [J].
ODWYER, PJ ;
LEYLANDJONES, B ;
ALONSO, MT ;
MARSONI, S ;
WITTES, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (11) :692-700